Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.…
Freenome (FRNM) Q3 2026 Earnings Call Transcript
Freenome (NASDAQ: FRNM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 363 employees.
The shares were at 9.360 USD on 20 November 2026, down 12.5% over 52 weeks. Its 52-week range is 9.280 USD to 17.48 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.04B USD.
Freenome reports return on equity of 17.4% and an operating margin of -43.8%.
It holds more cash than debt, a net cash position of 228.31M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 18.00 USD is 92.3% above the current price.